GLP-1 drugs may reduce the risk of cancer progressing, study suggests

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

The list of health benefits tied to the diabetes and weight loss drugs has been growing — approvals have been expanded to reduce risk of heart disease (Wegovy), to prevent worsening kidney disease (Ozempic) and to treat obstructive sleep apnea (Zepbound) — and researchers continue to look for other possibilities.

The latest research, which is not yet published in a peer-reviewed journal, adds to a growing number of early studies showing that GLP-1s could have anti-cancer effects.